Efficacy and safety of co-administration of EGF + GHRP-6 in the treatment of acute cerebral infarction of ischemic etiology.

Center for Genetic Engineering and Biotechnology (CIGB), in Havana0 个研究点目标入组 220 人开始时间: 2019年3月14日最近更新: 2024年8月19日

研究概览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

•1. Compliance with the diagnostic criteria (patients of both sexes, with a focal neurological defect caused by disturbances of the circulatory supply to a specific brain area, confirmed by computerized axial tomography images).
•2. Age between 19 and 80 years, both inclusive.
•3. Time between the onset of symptoms and the beginning of the administration of Serendictus less than 12 hours.
•4. Voluntariness of the patient (or family member) through the granting of informed consent (oral).

•1. Coma state (Glasgow scale less than 8).
•2. Score on the NIHSS scale <5 or > 20.
•3. When the neurological defect can be explained by another entity different from the acute cerebral infarction.
•4. Patients with neurological symptoms or signs that return to normal before the start of treatment.
•5. Severe and uncontrolled arterial hypertension (systolic >200 mmHg or diastolic> 120 mmHg) that does not descend after treatment.
•6. Arterial hypotension (systolic <95 mmHg) that does not respond to the usual treatment.
•7. How to install the clinical picture with seizures.
•8. Patients with basic neurological alterations that could interfere with the functional evaluation process during the course of the study.
•9. Patients diagnosed with malignant neoplasms.
•10. Pregnancy or lactation at the time of inclusion in the study (referred by the patient or family member).
•11. Obvious mental inability to issue consent and act accordingly with the study.

发起方

Center for Genetic Engineering and Biotechnology (CIGB), in Havana